ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
1.310
+0.020 (1.55%)
Feb 27, 2026, 4:00 PM EST - Market closed
ABVC BioPharma Revenue
ABVC BioPharma had revenue of $795.95K in the quarter ending September 30, 2025, with 104.47% growth. This brings the company's revenue in the last twelve months to $797.92K, up 56.52% year-over-year. In the year 2024, ABVC BioPharma had annual revenue of $509.59K with 234.31% growth.
Revenue (ttm)
$797.92K
Revenue Growth
+56.52%
P/S Ratio
40.54
Revenue / Employee
$41,996
Employees
19
Market Cap
32.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 509.59K | 357.16K | 234.31% |
| Dec 31, 2023 | 152.43K | -817.35K | -84.28% |
| Dec 31, 2022 | 969.78K | 613.99K | 172.57% |
| Dec 31, 2021 | 355.80K | -127.25K | -26.34% |
| Dec 31, 2020 | 483.05K | -218.67K | -31.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 8.96M |
| Dyadic International | 3.34M |
| Werewolf Therapeutics | 1.14M |
| RenovoRx | 928.00K |
| INmune Bio | 50.00K |
ABVC News
- 1 year ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewsWire
- 2 years ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 2 years ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire